Login to Your Account



Adventrx Restructures to Focus Efforts on ANX-530 and ANX-514

By Trista Morrison


Tuesday, October 21, 2008
A year after lead product CoFactor (ANX-510) failed a Phase IIb trial, Adventrx Pharmaceuticals Inc. is restructuring to focus on its chemotherapy emulsion products, ANX-530 and ANX-514. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription